Needham & Company LLC reiterated their buy rating on shares of Sensei Biotherapeutics (NASDAQ:FTH – Free Report) in a research report report published on Monday morning,Benzinga reports. They currently have a $56.00 price objective on the stock.
Other equities analysts also recently issued reports about the company. Citigroup increased their target price on Sensei Biotherapeutics from $55.00 to $60.00 and gave the stock a “buy” rating in a research report on Tuesday, November 10th. Citizens Jmp initiated coverage on Sensei Biotherapeutics in a report on Monday, July 20th. They issued an “outperform” rating and a $51.00 price target for the company. Guggenheim dropped their price objective on shares of Sensei Biotherapeutics from $70.00 to $69.00 and set a “buy” rating for the company in a research note on Wednesday, November 4th. Raymond James Financial assumed coverage on shares of Sensei Biotherapeutics in a report on Friday, July 31st. They set an “outperform” rating and a $56.00 price objective on the stock. Finally, BTIG Research reiterated a “buy” rating and set a $55.00 price objective on shares of Sensei Biotherapeutics in a report on Tuesday, October 27th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Sensei Biotherapeutics has an average rating of “Moderate Buy” and an average price target of $56.58.
View Our Latest Report on Sensei Biotherapeutics
Sensei Biotherapeutics Trading Down 3.5%
Shares of NASDAQ FTH opened at $8.72 on Monday. The firm has a market capitalization of $225.32 million, a P/E ratio of -0.06 and a beta of -0.15. Sensei Biotherapeutics has a 1-year low of $7.45 and a 1-year high of $42.14. The business’s fifty day moving average is $23.30.
Sensei Biotherapeutics (NASDAQ:FTH – Get Free Report) last issued its earnings results on Tuesday, November 3rd. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.13). On average, research analysts expect that Sensei Biotherapeutics will post -14.01 EPS for the current year.
Hedge Funds Weigh In On Sensei Biotherapeutics
Several hedge funds and other institutional investors have recently modified their holdings of FTH. Goldman Sachs Group Inc. purchased a new stake in shares of Sensei Biotherapeutics during the 3rd quarter worth about $2,050,000. Integral Health Asset Management LLC acquired a new stake in Sensei Biotherapeutics during the 3rd quarter worth approximately $7,138,000. Jump Financial LLC purchased a new position in Sensei Biotherapeutics in the third quarter valued at approximately $694,000. AWM Investment Company Inc. raised its holdings in Sensei Biotherapeutics by 4.5% in the third quarter. AWM Investment Company Inc. now owns 116,344 shares of the company’s stock valued at $3,460,000 after buying an additional 5,001 shares during the period. Finally, State Street Corp acquired a new position in Sensei Biotherapeutics during the third quarter valued at approximately $9,262,000. 10.50% of the stock is owned by institutional investors and hedge funds.
About Sensei Biotherapeutics
Sensei Biotherapeutics is a biotechnology company focused on developing immunotherapies for cancer. Its research centers on treatments intended to address immune suppression in the tumor microenvironment and help the body’s immune system recognize and attack cancer cells. The company’s publicly disclosed research programs have included SNS-101, an antibody designed to target VISTA, an immune checkpoint protein, and SNS-301, an investigational cancer immunotherapy. These programs were in development rather than marketed products.
Further Reading
- Five stocks we like better than Sensei Biotherapeutics
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Sensei Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensei Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
